Related Experiment Video
Updated: Jul 2, 2026
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
Impact of Thyroid Transcription Factor-1 Expression on Outcomes of Platinum-Based Chemoimmunotherapy in Advanced or
Ryohei Kamada1, Hiroshi Yokouchi1, Shohei Mizobuchi1
1Department of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan.
Background:
Thyroid transcription factor-1 (TTF-1) is a diagnostic biomarker in non-squamous (non-sq) non-small cell lung cancer (NSCLC). TTF-1 negativity has been associated with poor outcomes following immunotherapy and pemetrexed-based chemotherapy in advanced non-sq NSCLC. However, the impact of TTF-1 expression on chemoimmunotherapy efficacy regimens remains unclear.
Methods:
We retrospectively analyzed patients with advanced or recurrent non-sq NSCLC who received first-line platinum and pemetrexed plus pembrolizumab (Platinum/PEM/Pembro) or carboplatin and nab-paclitaxel plus atezolizumab (CBDCA/nab-PTX/Atezo) between March 2019 and May 2025 at our institution.
Results:
Among 67 patients, 44 were TTF-1 positive and 23 were TTF-1 negative. In the overall cohort, TTF-1-positive patients had significantly longer progression-free survival (PFS) and overall survival (OS) than TTF-1-negative patients. In the Platinum/PEM/Pembro group, PFS and OS did not differ by TTF-1 status (median PFS: 8.5 vs. 7.0 months; hazard ratio [HR], 0.85; 95% confidence interval [CI], 0.39-1.86, and median OS: 23.7 vs. 26.1 months; HR, 0.93; 95% CI, 0.36-2.35). In univariate analysis of the overall population, TTF-1 expression and performance status (PS) were significantly associated with PFS, while TTF-1 expression, PS, and histological type were significantly associated with OS. The Platinum/PEM/Pembro group had a higher relative dose intensity of concomitant chemotherapy, a greater median number of immune checkpoint inhibitor cycles, and a longer median treatment duration. Immune-related adverse events (irAEs) were more frequent with Platinum/PEM/Pembro (50.0% vs. 17.4%, p = 0.0164).
Conclusions:
Platinum/PEM/Pembro may be a therapeutic option for TTF-1-negative non-sq NSCLC with good PS and adenocarcinoma histology, although careful management of irAE is required.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...